SGLT inhibitors: A novel target for diabetes

Pharmaceutical Patent Analyst

Volumn 2, Issue 1, 2013, Pages 77-91

  Kanwal, Abhinav ^a   Banerjee, Sanjay K ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

3 (5 BENZOFURANYL) 1 [2 HYDROXY 6 [6 O (METHOXYCARBONYL) BETA DEXTRO GLUCOPYRANOSYL] 4 METHYLPHENYL] 1 PROPANONE; ANTIDIABETIC AGENT; BI 44847; CAFFEINE; CANAGLIFLOZIN; CSG 4524; DAPAGLIFLOZIN; EGT 0001442; EMPAGLIFLOZIN; EPIGALLOCATECHIN GALLATE; ERTUGLIFLOZIN; GLUCOSE; IPRAGLIFLOZIN; KGA 3235; KGT 1075; KGT 1611; LX 4211; METFORMIN; NSC 2833; PHLORIZIN; PLACEBO; PROTEIN INHIBITOR; REMOGLIFLOZIN; SERGLIFLOZIN ETABONATE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER INHIBITOR; TOFOGLIFLOZIN; TS 071; UNCLASSIFIED DRUG; UNINDEXED DRUG; YM 543;

ADD ON THERAPY; BACKACHE; BLADDER CANCER; BREAST CANCER; DIABETES MELLITUS; DIARRHEA; DRUG DOSAGE FORM; DRUG INDUSTRY; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL SYMPTOM; GENITAL TRACT INFECTION; GLAUCOMA; GLUCOSE ABSORPTION; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INFECTION; KIDNEY FAILURE; KIDNEY TUBULE ABSORPTION; LIVER INJURY; MULTICENTER STUDY (TOPIC); MYCOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; ROSACEA; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VAGINA CANDIDIASIS;

EID: 84875157685     PISSN: 20468954     EISSN: 20468962     Source Type: Journal    
DOI: 10.4155/ppa.12.78     Document Type: Review

References (26)

1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res. Clin. Pract. 94(3), 311-321 (2011).
2. Wright EM. Renal Na-glucose cotransporters. Am. J. Renal Physiol. 280, F10-F18 (2001).
3. Kipnes MS. Sodium-glucose cotransporter 2 inhibitors in the treatment of type 2 diabetes: A review of Phase II and III trials. Clin. Invest. 1(1), 145-156 (2011).
4. Rajesh R, Naren P, vidyasagar S. Sodium glucose co transporter 2 (SGLT2) inhibitors: A new sword for the treatment of type 2 diabetes mellitus. Int. J. Pharm. Sci. 1(2), 139-147 (2010).
5. Neumiller JJ, WhiteJr JR, Campbell RK. Sodium-glucose co-transport inhibitors progress and therapeutic potential in type 2 diabetes mellitus. Drugs70 (4), 377-385 (2010).
6. Reizer J, Reizer A, Saier MH Jr. A functional superfamily of sodium/solute symporters. BBA-Biomembranes 1197, 133-166 (1994).
7. Brown GK. Glucose transporters: Structure, function, and consequences of deficiency. J. Inherited Metab. Dis. 23, 237-246 (2000).
8. Wright EM, Turk, E. The sodium/glucose cotransport family SLC5. Pflugers Arch. 447, 510-518 (2004).
9. Vestri S, Okamoto MM, de Freitas HS et al Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. J. Membr. Biol. 182, 105-112 (2001).
10. Tabatabai NM, Sharma M, Blumenthal SS et al. Petering DH. Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic zucker rats enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic zucker rats. Diabetes Res. Clin. Pract. 83(1), e27-e30 (2009).
11. Rahmoune H, Thompson PW, Ward JM et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54, 3427-3434 (2005).
12. Ehrenkranz JR, Lewis NG, Kahn CR et al. Phlorizin: A review. Diabetes Metab. Res. Revs. 21, 31-38 (2005).
13. Chao EC, RR Henry. SGLT2 inhibition - a novel strategy for diabetes treatment. Nature Rev. Drug Discov. 9 (7), 551-559 (2010).
14. Oku A, K Ueta, K Arakawa et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 48, 1794-1800 (1999).
15. Meng W, Ellsworth BA, Nirschl AA et al. Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 51, 1145-1149 (2008).
16. Han S, Hagan DL, Taylor JR et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57, 1723-1729 (2008).
17. Bailey CJ, Day C. SGLT2 inhibitors: Glucuretic treatment for type 2 diabetes. Br. J. Diab. Vasc. Dis. 10, 193-199 (2010).
18. Devineni D, Morrow L, Hompesch M. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes. Metab. 14, 539-545 (2012).
19. Gallwitz B. Review of sitagliptin phosphate: A novel treatment for type 2 diabetes. Vasc. Health Risk Manag. 3(2), 203-210 (2007).
20. Komoroski B, Vachharajani N, Feng Y et al. Dapagliflozin, a novel,selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin. Pharmacol. Ther. 85, 513-519 (2009).
21. List JF, Woo V, Morales E et al. Sodium- glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32, 650-657 (2009).
22. Wilding JP, Norwood P, T'joen C et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: Applicability of a novel insulin-independent treatment. Diabetes Care 32, 1656-1662 (2009).
23. Bakris GL, Fonseca VA, Sharma K et al. Renal sodium-glucose transport: Role in diabetes and potential clinical implications. Kidney Int. 75, 1272-1277 (2009).
24. Zhou L, Cryan EV, D'Andrea MR et al. Human cardiomyocytes express high levels of Na+/glucose cotransporter 1 (SGLT1). J. Cell Biochem. 90, 339-346 (2003).
25. Banerjee SK, McGaffin KR, Pastor-Soler NM, F. et al. SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states, Cardiovasc. Res. 84, 111-118 (2009).
26. Banerjee SK, Wang DW, Alzamora R, Huang XN et al. SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathy. J. Mol. Cell. Cardiol. 49, 683-692 (2010).